The final of the 2023 SCOPE IP Bursary Awards took place on Thursday 29 June 2023. The award, now in its second year, attracted many entries the quality of which were extremely high.
Consent is a hot topic at the moment and the publication of the GMC Guidance on Consent [1] has rightfully refocussed our attention on it. Consent practices vary wildly and have been the subject of many of these surveys. Once...
5 February 2020
| Salina Zaheen, Yasmin Riaz
|
EYE - General
With 90% of the world’s visually impaired living in developing countries, Pakistan is no exception to this on-going global healthcare challenge. Despite massive leaps over the last few decades in targeting this issue, the World Health Organisation (WHO) reports that...
3 October 2022
| Rosie Brennan, Bernadetha Robert Shilio, Marcia Zondervan, Covadonga Bascaran
|
EYE - General
Global Citizen post - a new challenge I was looking for a new challenge. I had been in the same consultant post with a subspecialty interest in paediatrics and strabismus for 17 years and was rattling around in an empty...
In this retrospective review of 217 patients with Whipple’s disease (WD), the authors reviewed the presentations of those with ocular manifestations. Ocular signs of WD are under recognised, frequently resulting in misdiagnosis and mismanagement. Mayo Data Explorer, a Mayo Clinic...
“In the midst of tragedy, we start the comedy” – Agatha Christie, The ABC Murders. Throughout a career in medicine, we are often faced with tragedy. One of the coping mechanisms is to use humour to navigate the mini everyday...
As a foundation year doctor, I didn’t expect ophthalmology to feature much in acute medicine or surgery. Yet it kept appearing at the periphery – and when it did, it was often complex and unexpectedly urgent. A confused older patient...
The author provides a review of the current literature regarding the principles of classification, management protocols of acute ocular and periocular burns and the role of the burn and oculoplastic surgeon involved in their care. More than two-thirds of facial...
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...